SPOTLIGHT: Merck halts trial enrollment

Merck's giant migraine over the Vytorin data is spilling into one of its development programs. Researchers halted enrollment in a late-stage study of the cholesterol drug Cordaptive to ponder results from similar trials as well as the lessons learned from Vytorin. The trial will continue with 300 volunteers instead of the planned 900. Report

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.